Frequently asked questions

Not yet. On 24 July 2026 the EMA's CHMP issued a positive opinion recommending marketing authorisation in the European Union for obicetrapib as monotherapy (Ubeslo) and as a fixed-dose combination with ezetimibe (Evlarco). A European Commission decision was expected in the second half of 2026. No CETP inhibitor has ever been approved anywhere before this.

Once. REVEAL randomised 30,449 patients to anacetrapib or placebo on top of intensive atorvastatin and met its primary endpoint in 2017. Merck did not file, citing the modest absolute benefit and the drug's accumulation in adipose tissue. No other trial in the class has shown benefit, and PREVAIL, the obicetrapib outcomes trial, has not read out.

ILLUMINATE was stopped in December 2006 for excess mortality. The harm was traced to off-target effects on aldosterone, blood pressure and electrolytes rather than to CETP inhibition itself. The distinction matters: the drugs developed since do not share those effects, which is why the class continued at all.

On this evidence, no. Evacetrapib more than doubled HDL-C in 12,092 high-risk patients in ACCELERATE and the event curves did not separate. Dalcetrapib raised HDL-C by about a third in 15,871 patients in dal-OUTCOMES with no benefit. Both trials are usually cited as the end of the simple HDL hypothesis.

LDL cholesterol and apoB. In the phase 3 programme it lowered LDL-C by up to about 40% as monotherapy and roughly 50% combined with ezetimibe, on top of maximally tolerated therapy. The genetic evidence supports that framing: the cardiovascular effect of lifelong lower CETP tracks apoB-containing lipoproteins rather than HDL-C.

Obicetrapib is a once-daily oral tablet, taken in addition to a statin. That is its practical argument against the injectable alternatives for patients who have run out of oral options.

It is the safety question the class always answers. A pooled phase 3 safety analysis of 2,880 patients found no clinically significant blood pressure change with obicetrapib and comparable rates of hypertension events against placebo. Twelve months is still short for a chronic preventive drug.

CETP genotype has been linked to cognitive outcomes and to exceptional longevity in observational work, and the results are inconsistent. It is an open question rather than an established effect, which is why it has its own topic here.

Yes, modestly, and the effect differs between agents. Those papers are tagged Lipoprotein(a) here; the sister site lp-a.org covers Lp(a) itself in depth.

Yes. A genotype-selected trial (NCT05918861, n=2,000) is recruiting with primary completion in August 2027, testing the ADCY9 responder hypothesis that came out of dal-OUTCOMES. Most accounts of the class miss this.

It is written and edited independently. Summaries are written from published abstracts; the source always wins. See Methods.